I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Progressive myoclonus epilepsies (PMEs) comprise a group of hereditary disorders characterized by action myoclonus, epileptic seizures, and ataxia with progressive neurologic decline.\[[@ref1]\] Owing to clinical and molecular heterogeneity, PMEs present with various forms caused by different disease-causing genes. According to the Online Mendelian Inheritance in Man database and relevant literature, PMEs can be divided into 12 subtypes: Unverricht--Lundborg disease (EPM1A), EPM1B, Lafora body disease (EPM2A), Lafora body disease (EPM2B), EPM3, action myoclonus with or without renal failure syndrome (EPM4), PME-ataxia syndrome (EPM5), North Sea PME (EPM6), EPM7, EPM8, EPM9, and EPM10. The respective disease-causative genes are as follows: *CSTB, PRICKLE1, MELF, NHLRC1, KCTD7, *SCARB2*, PRICKLE2, GOSR2, KCNC1, CERS1, LMNB2*, and *PRDM8*.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]\] However, there are other neurogenetic diseases mainly characterized by myoclonus, epileptic seizures, and ataxia, such as myoclonus epilepsy and ragged red fibers, neuronal ceroid lipofuscinoses, sialidosis, dentatorubral-pallidoluysian atrophy (DRPLA), and neuronopathic Gaucher disease, while a literature also regarded these diseases as PMEs.\[[@ref1]\] In clinic, it is difficult to make an exact diagnosis among the various forms of PMEs due to homogeneous phenotypes. Moreover, other diseases, such as juvenile myoclonic epilepsy, inherited ataxia, and mitochondrial disease, also resemble or overlap PMEs in clinical features, which present challenges in the differential diagnosis. Therefore, the screening for the disease-related mutation of pathogenic genes is particularly valuable in the diagnosis of PMEs. Traditional Sanger sequencing lacks the efficiency to handle larger numbers of candidate genes associated with PMEs. As a powerful approach for genetic diagnostics in inherited Mendelian disorders, targeted next-generation sequencing (NGS) has increased the ability to rapidly and effectively sequence any genomic region of interest.\[[@ref14][@ref15]\]

In the present study, two brothers were confirmed as EPM4 with the application of a targeted NGS panel, which covers the causative genes of PMEs, juvenile myoclonic epilepsy,\[[@ref16]\] inherited ataxia, and mitochondrial disease. The investigators found a novel splice mutation of scavenger receptor class B, member 2 (*SCARB2*), and further validated the candidate variant by functional research based on the patient\'s tissues. Furthermore, literature data were reviewed to summarize the clinical and mutational spectrum of all reported EPM4 patients worldwide.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The present study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University. Written informed consent was obtained from all participants in the family and individuals in the control group.

Subject {#sec2-2}
-------

A family from Fujian Province, China, who presented with a PME phenotype, was recruited in the present study. Detailed clinical data, including clinical presentations, physical examinations, laboratory tests, and neuroimaging and electroencephalography (EEG) results, were collected. Three hundred unrelated healthy individuals with no known history of neurogenetic disease were collected and assigned as the control group.

Genetic testing of dentatorubral-pallidoluysian atrophy {#sec2-3}
-------------------------------------------------------

For the purpose of excluding DRPLA, the patient was tested for CAG trinucleotide repeats in the ATN1 gene of the proband by polymerase chain reaction (PCR), as previously described.\[[@ref17]\]

Targeted next-generation sequencing and sequence analysis {#sec2-4}
---------------------------------------------------------

Targeted NGS was performed on genomic DNA samples extracted from the proband and his elder brother\'s peripheral blood samples using a Blood Genomic Extraction Kit (Qiagen, Hilden, Germany). The sequences were performed by an NGS-based assay using the Illumina HiSeq2500 platform (Illumina, California, USA). The panel was prepared using a NimbleGen SeqCap EZ Choice kit (Roche, Basel, Switzerland), which included 927 disease-causative genes of the neurogenetic disease, containing progressive myoclonic epilepsy, hereditary ataxia, mitochondrial diseases, neuronal ceroid lipofuscinosis and other neurogenetic diseases. Targeted coding exons and intron-exon regions corresponded to 4.8 Mb of the genomic sequence.

First, the raw sequence reads were aligned to the human reference genome (UCSC hg 19) (<http://hgdownload.cse.ucsc.edu/>) using Burrows--Wheeler Aligner (Li and Durbin, 2009). Second, the gene-, region-, and filter-based levels of the variants were annotated using the ANNOVAR software (version Feb 11, 2013, GitHub, Philadelphia, USA). Then, the frequency of the variants was further determined using the dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), the 1000 Genomes Project (<http://ftp.ncbi.nih.gov/>), and the Exome Aggregation Consortium (<http://exac.broadinstitute.org/>). Finally, the filtered variants were classified according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines.

Sanger sequencing {#sec2-5}
-----------------

Sanger sequencing was further performed to verify the candidate variants, and cosegregation analysis was performed among family members. The candidate regions were amplified by PCR and sequenced using the ABI PRISM 3730 gene analyzer (Applied Biosystems, California, USA).

Reverse transcriptase polymerase chain reaction {#sec2-6}
-----------------------------------------------

To evaluate whether the candidate variants influence the expression of mRNA, total RNA was isolated from frozen muscle treated with TRIzol Reagent (Life Technologies, California, USA), and single-strand cDNA was prepared using the PrimeScript^®^ RTase Kit (Takara, Otsu, Japan). The candidate region of *SCARB2* was amplified and sequenced using the following primers: Forward: 5\'-TGACTATGAGAGTGTACAGG-3\'; Reverse: 5\'-TGGTCTTCCTGATTTGGGTG-3\'.

Western blot {#sec2-7}
------------

Protein was isolated from frozen muscle treated with RIPA and PMSF (Beyotime, Shanghai, China). Thirty microgram of total protein was resolved on 10% SDS-PAGE gels, and the proteins were transferred onto nitrocellulose (NC) membranes. Then, the NC membranes were blocked with 5% nonfat milk in Tris-buffered saline with Tween solution (0.01 mol/L of Tris HCl, 0.15 mol/L NaCl, and 0.1% Tween) and probed with the appropriate primary antibody (mouse anti-LIMP2 antibody, Santa Cruz Biotechnology, USA; mouse anti-glyceraldehyde phosphate dehydrogenase antibody, Beyotime, China). Next, the membranes were incubated with the appropriate peroxidase-labeled mouse anti-goat Ig and developed with enhanced chemiluminescent detection reagents (Beyotime, Shanghai, China).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Clinical features of the family {#sec2-8}
-------------------------------

The proband is a 23-year-old male. He began to experience myoclonic jerks of the upper limbs and shoulders at the age of 21, especially when he felt nervous or fell asleep. Five episodes of generalized tonic--clonic seizures occurred 2 years later without any medication. On examination, his intelligence was normal. There was prominent action myoclonus that involved the upper limbs and shoulders. The other neurologic examination revealed cerebellar features, including dysarthria, a broad-based gait, abnormal heel--knee--tibia test, and finger--nose test. Mild generalized skeletal muscle atrophy without fasciculations and *pes cavus* was also observed.

The routine blood biochemical test results, including normal serum blood urea nitrogen, creatinine, and urinalysis, were unremarkable. EEG revealed multifocal spike and wave complexes, especially in the left parietal lobe, occipital lobe, and temporal lobe \[[Figure 1a](#F1){ref-type="fig"}\]. Brain MRI revealed mild cerebellar atrophy \[Figure [1b](#F1){ref-type="fig"} and [1c](#F1){ref-type="fig"}\]. Muscle biopsy presented with certain muscle atrophy and other less obvious signs, but there were no ragged red fibers \[[Figure 1d](#F1){ref-type="fig"}\].

![The auxiliary examinations of the proband. (a) EEG revealed multifocal spike and wave complexes, especially in the left parietal lobe, occipital lobe, and temporal lobe. (b) Axial brain MRI revealed mild cerebellar atrophy. (c) Transverse MRI scan revealed mild cerebellar atrophy. (d) Muscle biopsy presented with certain muscle atrophy and other less obvious signs (H and E, original magnification ×100). MRI: Magnetic resonance imaging; EEG: Electroencephalography.](CMJ-131-1575-g001){#F1}

The elder brother of the proband was found to have similar symptoms at the age of 20 years, with myoclonus, ataxia, and generalized tonic-clonic seizures. He started to experience anxiety and myoclonic jerks of the upper limbs and presented with three generalized episodes of tonic-clonic seizures and loss of consciousness in 1 year. After the medication of sodium valproate and lamotrigine, the symptom of epilepsy did not occur. The neurologic examination revealed ataxia and muscle weakness. This patient did not undergo blood biochemical tests, brain MRI, and muscle biopsy.

Dentatorubral--pallidoluysian atrophy CAG trinucleotide repeats analysis {#sec2-9}
------------------------------------------------------------------------

The PCR analysis demonstrated that the number of ATN1 CAG repeats was within the normal range in the proband.

Identification of variants by targeted next-generation sequencing analysis {#sec2-10}
--------------------------------------------------------------------------

Targeted NGS was performed in the two patients. The coverage of the fraction of the target base is presented in [Supplementary Table 1](#T1){ref-type="table"}. The mean coverage of the target bases was 92.1698 (II1) and 111.7527 (II2), respectively. Furthermore, the total SNP variants, including SNPs, noncoding region variants, synonymous mutations, and missense mutations, were 3499 (II1) and 3082 (II2), respectively, while the total initial map of insertion and deletion (INDEL) variants, including insertion and deletion, were 161 (II1) and 180 (II2), respectively. Through the further bioinformatic analysis of these two patients, it was found that these patients harbored a splice-site homozygous mutation in the *SCARB2* gene (c.995-1G\>A), which was an unreported splicing variant.

###### 

The coverage of the fraction of target base of II1 and II2

  Items                                               II1         II2
  --------------------------------------------------- ----------- -----------
  Total read                                          5,637,906   6,396,240
  Total mapped read                                   5,575,859   6,311,962
  Unique mapped                                       5,255,824   5,982,202
  No-mismatch mapped                                  3,509,971   4,152,867
  Mismatch alignment bases rate                       0.3774      0.3507
  Reads on target regions                             4,037,140   4,883,548
  Fraction on target regions                          0.7161      0.7635
  Fraction on target regions covered by reads         0.9982      0.9987
  Unique mapped reads on target regions               3,832,984   4,658,405
  No-mismatch reads on target regions                 2,577,212   3,232,079
  Reads on target ± 150 regions                       4,652,214   5,360,719
  Fraction on target ± 150 regions                    0.8252      0.8381
  Fraction on target ± 150 regions covered by reads   0.996       0.9961
  Unique mapped reads on target ± 150 regions         4,407,479   5,100,383
  No-mismatch reads on target ± 150 regions           2,937,340   3,524,865
  Reads on target ± 500 regions                       4,801,824   5,411,318
  Fraction on target ± 500 regions                    0.8517      0.846
  Fraction on target ± 500 regions covered by reads   0.8957      0.8004
  Unique mapped reads on target ± 500 regions         4,542,903   5,145,900
  No-mismatch reads on target ± 500 regions           3,011,736   3,551,922
  Fraction of target bases covered                    0.9982      0.9987
  Fraction of target bases covered with 0\~5X         0.012       0.0071
  Fraction of target bases covered with 5\~10X        0.0171      0.0099
  Fraction of target bases covered with 10\~15X       0.0207      0.0122
  Fraction of target bases covered with 15\~20X       0.0257      0.0138
  Fraction of target bases covered with 20\~25X       0.0316      0.0157
  Fraction of target bases covered with 25\~30X       0.0355      0.0179
  Fraction of target bases covered with 30\~35X       0.0382      0.0222
  Fraction of target bases covered with 35\~40X       0.0417      0.0252
  Fraction of target bases covered with 40\~45X       0.0439      0.0287
  Fraction of target bases covered with 45\~50X       0.0452      0.0308
  Fraction of target bases covered with \>50X         0.6865      0.8152
  Mean Coverage of target bases                       92.1698     111.7527

Sanger sequencing and cosegregation analysis {#sec2-11}
--------------------------------------------

The *SCARB2* c.995-1G\>A homozygous mutation identified by targeted NGS was further confirmed in the two brothers by Sanger sequencing \[[Figure 2](#F2){ref-type="fig"}\]. The homozygous mutation was also found in his elder brother, and *SCARB2* c.995-1G\>A was heterozygous in his unaffected parents \[[Figure 2](#F2){ref-type="fig"}\]. Meanwhile, the mutation was not detected in the 300 unrelated controls. Therefore, the *SCARB2* c.995-1G\>A homozygous mutation cosegregated with the PME family.

![Sanger sequencing of the family with progressive myoclonus epilepsies. The two brothers were tested for the homozygous splice mutation (c.995-1G\>A) of the *SCARB2* gene. Then, their parents were tested for heterozygous mutations of the *SCARB2* gene. The arrow indicated the homozygous splice mutation (c.995-1G\>A).](CMJ-131-1575-g002){#F2}

SCARB2 gene and protein expression analysis {#sec2-12}
-------------------------------------------

To evaluate the meaning of the *SCARB2* c.995-1G\>A homozygous mutation, the cDNA and protein levels of *SCARB2* were analyzed by RT-PCR and Western blot, respectively. After Sanger sequencing to the cDNA of the *SCARB2* gene, as presented in [Figure 3a](#F3){ref-type="fig"}, a c.995-1036del42 mutation was observed in the proband. Furthermore, Western blot was performed to evaluate the expression and quality of the *SCARB2* protein. As presented in [Figure 3b](#F3){ref-type="fig"}, a truncated *SCARB2* protein is observed, which is accordant with the c.995-1036del42 mutation in the cDNA of patients who harbored the *SCARB2* c.995-1G\>A homozygous mutation. Compared to the full length of the 72,000 of the *SCARB2* protein in healthy controls, the expression of the truncated *SCARB2* protein that weighted from 43,000 to 55,000 significantly decreased (*t* = 2.887, *P* = 0.0447) \[[Figure 3b](#F3){ref-type="fig"}\].

![*SCARB2* gene expression and protein expression analysis of the proband. (a) Sanger sequencing to the cDNA of the *SCARB2* gene: a c. 995-1036del42 mutation was observed in the proband. (b) Western blot analysis of the protein obtained from the muscle of proband and controls. Compared to the full length of the 72,000 of *SCARB2* protein in healthy controls, the expression of the truncated *SCARB2* protein that weighted from 43,000 to 55,000 significantly decreased (*t* = 2.887, *P* = 0.0447). The arrow indicated a 43,000-protein band appeared in patients but a 72,000 band in control.](CMJ-131-1575-g003){#F3}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In the present study, targeted NGS technique was applied to screen disease-causative genes in a PME family. A novel *SCARB2* splicing homozygous variant c.995-1G\>A was identified in this family. According to the standards and guidelines of the ACMG, the variant was classified as a pathogenic variant. Further functional analysis confirmed that the c.995-1G\>A variant can lead to the loss function of *SCARB2* protein. Therefore, the two brothers were finally diagnostically confirmed with EPM4.

EPM4 is a rare form of PMEs and is an autosomal recessive inherited disorder caused by homozygous mutation and compound heterozygous mutation in the *SCARB2* gene.\[[@ref18][@ref19]\] Due to the genetic heterogeneity and clinical variability of PMEs, it is often challenging to detect particular gene mutations by depending solely on phenotypes. In clinic, there is a need to establish a molecular diagnostic strategy for the screening of disease-causative genes in PME cases. Targeted NGS is a high-throughput and cost-effective method to screen genomic regions of interest. This approach has been applied for inherited Mendelian disorders.\[[@ref14][@ref15]\] Once the panel is established, it can be used for the same genomic region in different cases. In the present study, a panel that included 927 disease-causative genes of neurogenetic diseases was established and used for detecting the culprit genes of PMEs and other neurogenetic diseases. However, the disadvantage of targeted NGS is that the approach cannot accurately detect trinucleotide repeats and copy number variations. Hence, for PME cases, before applying targeted NGS, the CAG trinucleotide repeats of DRPLA needs to be initially screened.

To date, only few EPM4 patients have been recorded worldwide. The correlation of genotypes and phenotypes among EPM4 patients has seldom been summarized in previous literature. The studies conducted by the investigators identified both mutant alleles in the two brothers with EPM4, providing more information to further analyze the clinical features and mutational spectrum of all reported EPM4 patients \[[Table 1](#T2){ref-type="table"}\].\[[@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30]\] According to the literature review and the present study, the median age of onset is 20 years (range: 11--52 years) and the median age of death is 30.5 years (range: 23--59 years). All EPM4 patients begin with three typical manifestations: action myoclonus, generalized seizures, and ataxia. However, the median onset age of these three typical manifestations shows little statistical difference: action myoclonus presents at 21 years (range: 14--57 years), generalized seizure presents at 21.5 years (range: 16--63 years), and ataxia presents at 20.5 years (range: 14--58 years). With regard to renal failure, 11 patients suffered from this and developed EPM4 in adolescence (median: 17 years), while the other 17 patients had no renal dysfunction, but presented initial signs at a later age (median: 22 years) (*P* = 0.033). In addition, other malfunctions were also observed in previous studies: hearing loss occurred in two patients, cognitive decline occurred in two patients, and demyelinating polyneuropathy occurred in four patients.\[[@ref22][@ref23][@ref24][@ref25]\] In the present study, it was found that the proband and his brother presented with talipes cavus, which may suggest that they have acquired peripheral neuropathy.

###### 

Literature data on the clinical and mutational features of all reported EPM4

  Reference                                            Case                       Mutation type              Exon/intron                    Nucleotide mutation                 Protein alteration   Location of mutation        Sex                     
  ---------------------------------------------------- -------------------------- -------------------------- ------------------------------ ----------------------------------- -------------------- --------------------------- ----------------------- --------------------------------------------
  Balreira *et al*. Hum Mol Genet\[[@ref18]\]          1                          Homozygote                 Exon 4                         c.533G\>A                           W178X                GBA binding domain          Female                  
                                                       2                          Homozygote                 Exon 4                         c.533G\>A                           W178X                GBA binding domain          Female                  
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         3                          Homozygote                 Intron 10                      c.1239+1G\>T                        N                    CD36 like domain            Female                  
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         4                          Homozygote                 Exon 4                         c.435_436insAG                      W146SfsX16           GBA binding domain          Female                  
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         5                          Compound heterozygote      Exon 3                         c.296 delA                          N99IfsX34            CD36 like domain            Male                    
                                                                                                             Intron 5                       c.704+5G\>A                         N                    GBA binding domain                                  
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         6                          Homozygote                 Exon 7                         c.862C\>T                           Q288X                GBA binding domain          --                      
  Dardis *et al*. Mol Genet Metab\[[@ref20]\]          7                          Homozygote                 Exon 8                         c.1087C\>A                          H363N                CD36 like domain            Female                  
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              8                          Homozygote                 Intron 8                       c.1116-2A\>C                        N                    CD36 like domain            Male                    
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              9                          Homozygote                 Intron 5                       c.704+1G\>C                         N                    GBA binding domain          Male                    
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              10                         Homozygote                 Exon 11                        c.1258delG                          E420RfsX5            CD36 like domain            Female                  
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              11                         Homozygote                 Exon 5                         c.666delCCTTA                       Y222X                GBA binding domain          Female                  
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              12                         Compound heterozygote      Intron 3                       c.424-2A\>C                         N                    CD36 like domain            Female                  
                                                                                                             Exon 8                         c.1087C\>A                          H363N                CD36 like domain                                    
  Dibbens *et al*. Arch Neurol\[[@ref22]\]             13                         Compound heterozygote      Exon 7                         c.862C\>T                           Q288X                GBA binding domain          Male                    
                                                                                                             Intron 9                       c.1187+3insT                        N                    CD36 like domain                                    
  Hopfner *et al*. BMC Neurol\[[@ref23]\]              14                         Homozygote                 Exon 1                         c.111delC                           I37MfsX7             CD36 like domain            Male                    
                                                       15                         Homozygote                 Exon 1                         c.111delC                           I37MfsX7             CD36 like domain            Male                    
                                                       16                         Homozygote                 Exon 1                         c.111delC                           I37MfsX7             CD36 like domain            Female                  
  Perandones *et al*. Mov Disord\[[@ref24]\]           17                         Homozygote                 Intron 5                       c.704+1G\>A                         N                    GBA binding domain          Female                  
  Guerrero-López *et al*. Mov Disord\[[@ref28]\]       18                         Homozygote                 Exon 8                         c.1015insT                          F339FfsX9            CD36 like domain            Female                  
  Higashiyama *et al*. Mov Disord\[[@ref29]\]          19                         Homozygote                 Exon 11                        c.1385_1390del6insATGCATGCACC       G462DfsX34           TM domain                   Female                  
                                                       20                         Homozygote                 Exon 11                        c.1385_1390del6insATGCATGCACC       G462DfsX34           TM domain                   Male                    
  Fu *et al*. Neuropathol Appl Neurobiol\[[@ref25]\]   21                         Homozygote                 Exon 11                        c.1385_1390del6insATGCATGCACC       G462DfsX34           TM domain                   Male                    
  Fu *et al*. Neuropathol Appl Neurobiol\[[@ref25]\]   22                         Homozygote                 Exon 3                         c.361C\>T                           R121X                CD36 like domain            Female                  
  Zeigler *et al*. J Neurol Sci\[[@ref27]\]            23                         Homozygote                 Exon 11                        c.1270C\>T                          R424X                CD36 like domain            Male                    
                                                       24                         Homozygote                 Exon 11                        c.1270C\>T                          R424X                CD36 like domain            Female                  
  He *et al*. Clin Genet\[[@ref26]\]                   25                         Homozygote                 Exon 11                        c.1270C\>T                          R424X                CD36 like domain            Female                  
                                                       26                         Homozygote                 Exon 11                        c.1270C\>T                          R424X                CD36 like domain            Female                  
  This study                                           27                         Homozygote                 Exon 7                         c.995-1G\>A                         N                    CD36 like domain            Male                    
                                                       28                         Homozygote                 Exon 7                         c.995-1G\>A                         N                    CD36 like domain            Male                    
                                                                                                                                                                                                                                                         
  **Reference**                                        **Age of onset (years)**   **Age at death (years)**   **Action myoclonus (years)**   **Tonic clonic seizures (years)**   **Ataxia (years)**   **Renal failure (years)**   **Phenotype**           **Other specific phenotype**
                                                                                                                                                                                                                                                         
  Balreira *et al*. Hum Mol Genet\[[@ref18]\]          15                         23                         15                             --                                  18                   18                          With renal failure      N
                                                       17                         26                         15                             --                                  17                   21                          With renal failure      N
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         11                         --                         --                             --                                  --                   --                          With renal failure      N
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         --                         --                         --                             --                                  --                   --                          With renal failure      N
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         11                         --                         --                             --                                  --                   --                          With renal failure      N
  Berkovic *et al*. Am J Hum Genet\[[@ref19]\]         --                         --                         --                             --                                  --                   --                          With renal failure      N
  Dardis *et al*. Mol Genet Metab\[[@ref20]\]          26                         --                         26                             27                                  26                   N                           Without renal failure   N
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              14                         29                         14                             17                                  17                   N                           Without renal failure   N
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              15                         27                         15                             16                                  16                   N                           Without renal failure   N
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              23                         33                         23                             23                                  24                   N                           Without renal failure   N
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              25                         40                         25                             28                                  31                   N                           Without renal failure   N
  Dibbens *et al*. Ann Neurol\[[@ref21]\]              26                         32                         26                             26                                  27.5                 N                           Without renal failure   N
  Dibbens *et al*. Arch Neurol\[[@ref22]\]             16                         --                         16                             20                                  20                   N                           Without renal failure   Demyelinating polyneuropathy
  Hopfner *et al*. BMC Neurol\[[@ref23]\]              14                         31                         14                             20                                  14                   --                          With renal failure      Demyelinating polyneuropathy
                                                       20                         38                         26                             32                                  20                   --                          With renal failure      Hearing loss, demyelinating polyneuropathy
                                                       20                         34                         20                             20                                  20                   --                          With renal failure      Demyelinating polyneuropathy
  Perandones *et al*. Mov Disord\[[@ref24]\]           21                         --                         23                             25                                  21                   25                          With renal failure      Hearing loss
  Guerrero-López *et al*. Mov Disord\[[@ref28]\]       22                         --                         22                             22                                  30                   N                           Without renal failure   N
  Higashiyama *et al*. Mov Disord\[[@ref29]\]          43                         --                         43                             58                                  58                   N                           Without renal failure   N
                                                       52                         --                         57                             63                                  52                   N                           Without renal failure   Acute ischemic stroke
  Fu *et al*. Neuropathol Appl Neurobiol\[[@ref25]\]   45                         59                         48                             --                                  51                   N                           Without renal failure   Dementia
  Fu *et al*. Neuropathol Appl Neurobiol\[[@ref25]\]   20                         28                         20                             20                                  20                   N                           Without renal failure   Cognitive decline
  Zeigler *et al*. J Neurol Sci\[[@ref27]\]            17                         30                         17                             17                                  17                   29                          With renal failure      N
                                                       17                         27                         17                             17                                  17                   N                           Without renal failure   
  He *et al*. Clin Genet\[[@ref26]\]                   21                         --                         21                             25                                  22                   N                           Without renal failure   N
                                                       27                         --                         27                             N                                   27                   N                           Without renal failure   
  This study                                           21                         --                         21                             21                                  21                   N                           Without renal failure   Talipes cavus
                                                       20                         --                         20                             20                                  20                   N                           Without renal failure   Talipes cavus

--: Not mention in the literature; N: Do not have the symptom; GBA: Beta-glucocerebrosidase; TM: Transmembrane.

The *SCARB2* gene encodes *SCARB2* protein in humans and is also known as lysosomal integral membrane protein type-2 (LIMP2), which is a disease causative of EPM4, and is associated with Parkinson\'s disease.\[[@ref18][@ref19][@ref31][@ref32]\] LIMP2, which is a nonspecifically expressed transmembrane (TM) protein, is mainly located in lysosomes and endosomes.\[[@ref33]\] While bounding with beta-glucocerebrosidase (GBA), LIMP2 can transfer GBA from the endoplasmic reticulum to the lysosome.\[[@ref34][@ref35][@ref36][@ref37][@ref38][@ref39]\] *SCARB2* protein comprises two TM domains and one CD36-like domain, which contains a highly conserved coiled-coil domain (residue: 145-288 aa) that binds GBA \[[Figure 4](#F4){ref-type="fig"}\].\[[@ref35][@ref36][@ref37]\] Mutations in the *SCARB2* gene result in decreasing and anomaly location of *SCARB2* protein, affecting the combination of SCARB and GBA.

![The structure of the *SCARB2* gene and the reported mutation of *SCARB2*. GBA: Beta-glucocerebrosidase; TM: Transmembrane.](CMJ-131-1575-g004){#F4}

The genotype and phenotype correlation of all reported EPM4 patients and the two brothers, including the 19 *SCARB2* gene mutations in 28 EPM4 patients, is summarized in the present study \[[Table 1](#T2){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}\].\[[@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30]\] Among these 19 mutations, 16 mutations (84.21%) were homozygous mutations, while only 3 mutations were compound heterozygous. The mutation types of *SCARB2* were nonsense, frameshift, and splice-site mutations, which can be assumed to disrupt gene function, leading to the complete absence of the gene product through the lack of transcription or nonsense-mediated decay of the altered transcript. For the phenotype with renal failure, seven mutations were found in 11 patients, of which the four mutations located in the GBA-binding domain may directly disrupt *SCARB2* bounding with GBA. Merely two mutations were not located in the GBA-binding domain. Although the I37MfsX7 homozygous mutation was located in this domain, it was a frameshift mutation that may produce a truncated protein with no GBA-binding domain. For the phenotype without renal failure, there were 11 homozygous mutations. Among these, eight mutations were located after the GBA-binding domain, which may not affect the combination of GBA and *SCARB2*, while two mutations were compound heterozygous mutations. Merely one mutation was located in the TM domain, which led to a late-onset phenotype.\[[@ref25][@ref29]\] These data possibly reveal that the functional domains of the *SCARB2* gene are associated with the EPM4 phenotype. Interestingly, there was a marked variability of clinical features between these two patients in EPM4 families (family 17) with the same nucleotide position (R424X), and the variability was also found in family 14 (c.704+1G\>A) though follow-up studies.\[[@ref27][@ref30]\] Hence, it could be speculated that the phenotypic difference may be due to genetic modifiers or environmental factors. Therefore, more data need to be acquired before a specific phenotype--genotype correlation could be determined.

In conclusion, the present study reported two EPM4 brothers with a novel splice mutation in the *SCARB2* gene detected by targeted NGS analysis. A literature review revealed that pathogenic mutations of the *SCARB2* gene in EPM4 patients are homozygous mutations rather than compound heterozygous mutations. The mutations in the different functional domains of *SCARB2* appear to be associated with the phenotype of EPM4.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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